Resistin is associated with impaired endothelial function and an increased rate of MACE in patients with PAD. Further research is needed to determine the potential mechanism by which resistin may increase MACE, and prospective studies should determine whether decreasing resistin has therapeutic benefit in patients with PAD.
Objectives: In light of the increasing complexity of infrainguinal disease managed by endovascular therapy, a retrograde approach using pedal access is often considered, either initially or after failed attempts with a more conventional antegrade approach. To date, there have been no studies that compare procedural details and outcomes after these two approaches in patients with equivalent disease characteristics.
Methods: Patients from three institutions undergoing retrograde approaches to infrainguinal occlusive disease were identified from the multidisciplinary multicenter XLPAD (Excellence in Peripheral Artery Disease) registry between 2007 and 2015. These patients were matched 1:1 based on (in order of priority) age (610 years), gender, comorbidities (diabetes, end-stage renal failure), indication for procedure (claudication vs critical limb ischemia), presence of concurrent inflow procedure, and tibial runoff characteristics. All study patients underwent additional independent review of charts and angiograms. Outcomes included technical success, major adverse limb events (MALE), and overall cost (estimated by device use). Data were analyzed using Cochran-Mantel-Haenszel and two-sided Wilcoxon rank sum statistics.
Results: A total of 116 patients (58 antegrade and 58 retrograde) were included. There were 46 (79%) patients who underwent a retrograde approach and had a failed attempt at antegrade approach. In four cases (8.7%), the failed antegrade attempt was in a separate procedure. There was no difference in lesion length between the 2 groups (162.3 6 105.3 mm vs 132.0 6 79.4 mm; P ¼ .27). The retrograde approach was associated with significantly longer procedural time (193 6 75 minutes vs 126 6 64 minus; P < .01), but no significant difference in technical success (91% vs 96%; P ¼ .24). Although there was no significant difference in perioperative morbidity, patients treated with a retrograde approach had a higher rate of myocardial infarction (MI) at 1 year (7% vs 0%; P ¼ .04). At 1 year, the retrograde approach group had lower rate of major and minor amputations (total amputation, 9% vs 22%; P ¼ .04; minor, 5% vs 16%; P ¼ .07; major, 3% vs 10%; P ¼ .14), but no difference in mortality (9% vs 5%; P ¼ .47). There was no difference in overall mean procedural costs ($4268.9 6 $2914.1 vs $3682.5 6 $2941.6; P ¼ .07).
Conclusions: In patients with similar disease characteristics, a retrograde approach to infrainguinal occlusions was associated with improved limb salvage, but also longer procedural time, as the technique is often employed after failed antegrade attempts, and no difference in procedural cost. Our findings suggest that earlier consideration of a pedal access may improve overall efficiency and possibly impact limb salvage rates.
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